H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $15 from $11 and keeps a Buy rating on the shares after the company announced the acquisition of the U.S. rights to Amglidia.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.